Affinage

MEF2D

Myocyte-specific enhancer factor 2D · UniProt Q14814

Length
521 aa
Mass
55.9 kDa
Annotated
2026-06-10
100 papers in source corpus 44 papers cited in narrative 44 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MEF2D is a MADS-box transcription factor that directs tissue-specific gene programs by binding MEF2 consensus elements at target promoters and enhancers, acting as either an activator or a repressor depending on its cofactor context (PMID:7760790, PMID:25801704). In skeletal muscle it cooperates with myogenin to recruit the SWI/SNF ATPase Brg1 and open chromatin at late muscle genes, and is sufficient with myogenin to drive differentiation (PMID:16424906); an alternatively spliced β-domain promotes higher-order assembly into nuclear condensates that serve as a platform for myogenic regulatory factors (PMID:36898987). Its DNA-binding repertoire is steered by partner factors: CRX redirects MEF2D to retina-specific enhancers lacking canonical sites (PMID:25801704), Sp1 enables activation of promoters without MEF2 elements (PMID:12213324), and switching between repressive HDAC complexes and the p300 coactivator toggles MEF2D between repressor and activator states (PMID:20590529, PMID:31678303). MEF2D activity is tuned by an extensive post-translational network: inhibitory phosphorylation by GSK3β and CDK5 (PMID:19801631, PMID:25417143), activating phosphorylation by ATM after DNA damage (PMID:24672010), acetylation by p300 (opposed by SIRT7 deacetylation) (PMID:31678303), and demethylation by KDM1A (PMID:34307695), while its abundance is controlled by oxidation-accelerated chaperone-mediated autophagy through Hsc70 (PMID:19119233, PMID:24219011) and by USP14-mediated deubiquitination that protects it from MDM2-dependent proteasomal degradation (PMID:37828611). A pool of MEF2D localizes to neuronal mitochondria via an N-terminal motif and mtHsp70, where it activates ND6 transcription to sustain complex I activity and neuronal survival (PMID:21393861). Through these activities MEF2D supports neuronal survival programs (Nur77, bcl-w) (PMID:23536182, PMID:19458239), drives pathological cardiac remodeling and represses PTEN in cardiomyocytes (PMID:18079970, PMID:26294766), and shapes adaptive and innate immunity by partnering with Foxp3 in Tregs and controlling type-2 lymphocyte and T-follicular-helper differentiation (PMID:32790649, PMID:38935708, PMID:36961907). MEF2D is oncogenic in multiple contexts, activating PD-L1, ZEB1, and integrin programs in carcinoma (PMID:31678303, PMID:27364559, PMID:37828611) and acting through chromatin-binding fusion proteins (MEF2D-HNRNPUL1, MEF2D-DAZAP1, MEF2D-BCL9) with enhanced transactivation to drive B-cell acute lymphoblastic leukemia (PMID:35544603, PMID:15744350, PMID:27824051).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 1995 High

    Established MEF2D as a sequence-specific DNA-binding transcription factor that mediates inducible gene expression, defining its core molecular activity.

    Evidence EMSA, transfection reconstitution in NIH 3T3 cells, and domain-swap analysis at the c-jun promoter

    PMID:7760790

    Open questions at the time
    • Did not identify cofactors mediating activation in vivo
    • Mechanism shared with SRF inferred, not directly tested
  2. 2006 High

    Showed how MEF2D drives muscle gene programs at the chromatin level by cooperating with myogenin to recruit the Brg1 chromatin remodeler.

    Evidence ChIP in cells and embryonic tissue, ectopic co-expression, and Brg1 dominant-negative/knockdown chromatin accessibility assays

    PMID:16424906

    Open questions at the time
    • Direct MEF2D-Brg1 contact not biochemically resolved
    • Order of recruitment relative to MyoD not fully defined
  3. 2008 High

    Established a required, dosage-sensitive role for MEF2D in stress-dependent pathological cardiac remodeling, distinguishing it as a driver of the fetal gene program.

    Evidence Conditional MEF2D knockout, pressure-overload and adrenergic stimulation models, and transgenic overexpression in mouse heart

    PMID:18079970

    Open questions at the time
    • Direct cardiac target genes not enumerated in this study
    • Cofactor dependency in cardiomyocytes not defined
  4. 2009 High

    Defined MEF2D protein turnover via chaperone-mediated autophagy and linked its dysregulation to Parkinson's disease through alpha-synuclein.

    Evidence Reciprocal Co-IP with Hsc70, CMA inhibition assays, alpha-synuclein transgenic mouse, and human PD brain analysis

    PMID:19119233

    Open questions at the time
    • Signals triggering cytoplasmic shuttling not defined
    • Lysosomal translocation machinery for MEF2D not detailed
  5. 2009 High

    Identified GSK3β as a direct inhibitory kinase coupling neuronal activity withdrawal to MEF2D inactivation and neuronal death.

    Evidence In vitro kinase assay with site-directed mutagenesis and GSK3β-resistant mutant rescue in cerebellar granule neurons

    PMID:19801631

    Open questions at the time
    • Phosphatase reversing these sites not identified
    • Phosphorylation effect on cofactor binding not resolved
  6. 2011 High

    Revealed an unexpected mitochondrial pool of MEF2D that directly drives ND6 transcription to support complex I activity and neuronal survival.

    Evidence ICC, immunoelectron microscopy, fractionation, ChIP on mtDNA, dominant-negative construct, MPTP mouse model, and PD brain tissue

    PMID:21393861

    Open questions at the time
    • Import mechanism beyond N-terminal motif/mtHsp70 unresolved
    • Regulation of nuclear vs mitochondrial partitioning unknown
  7. 2013 High

    Mapped multiple post-translational and cofactor controls on MEF2D activity (CDK5 inhibitory phosphorylation, O-GlcNAc, Nur77 promoter binding) governing neuronal and myogenic outputs.

    Evidence CDK5 kinase/siRNA in ICH model, O-GlcNAc biochemistry and ChIP in C2C12, and MEF2D ChIP at the Nur77 promoter with in vivo Nur77 epistasis

    PMID:23523791 PMID:23536182 PMID:25417143

    Open questions at the time
    • Cross-talk between distinct modifications not integrated
    • O-GlcNAc transferase specificity for MEF2D isoforms not resolved
  8. 2014 High

    Established opposing stress-responsive controls on MEF2D: ATM activates it to promote survival after DNA damage, while oxidative modification accelerates its CMA degradation.

    Evidence In vitro kinase assays, phosphomimetic/oxidation-resistant mutant rescue, Mef2d KO mice, and PD brain tissue (two studies)

    PMID:24219011 PMID:24672010

    Open questions at the time
    • Integration of activating phosphorylation with degradation signals unclear
    • Sites of oxidative modification not fully mapped
  9. 2015 High

    Demonstrated context-dependent target selection (CRX-directed retinal enhancers) and a cardioprotective role via direct PTEN activation restraining PI3K/Akt and cell-cycle re-entry.

    Evidence ChIP-seq with MEF2D-CRX Co-IP in retina, and siRNA knockdown with RNA-seq and PTEN ChIP in neonatal cardiomyocytes

    PMID:25801704 PMID:26294766

    Open questions at the time
    • Determinants of partner choice at noncanonical sites unclear
    • Cardiomyocyte vs retina cofactor differences not unified
  10. 2016 Medium

    Identified recurrent MEF2D rearrangements in B-ALL with enhanced transcriptional activity, HDAC9 activation, and HDAC-inhibitor sensitivity, establishing MEF2D fusions as leukemia drivers.

    Evidence RNA-seq of 560 ALL cases, transformation assays, and HDAC inhibitor sensitivity testing

    PMID:27824051

    Open questions at the time
    • Mechanistic basis of enhanced activity not resolved in this study
    • Fusion partner contributions not dissected
  11. 2019 High

    Defined MEF2D as a direct activator of the PD-L1 (CD274) gene under acetylation control, linking it to tumor immune evasion.

    Evidence ChIP, reciprocal Co-IP with p300/SIRT7, luciferase reporter, KO cells, and immune-competent allograft tumor models

    PMID:31678303

    Open questions at the time
    • Generality of PD-L1 regulation beyond HCC not established
    • Relationship between acetylation and methylation control unclear
  12. 2020 High

    Showed that Foxp3 redirects MEF2D away from canonical HDAC complexes to acquire Treg-specific effector functions, embedding MEF2D in immune tolerance.

    Evidence Conditional MEF2D KO in Tregs, MEF2D-Foxp3 Co-IP, and allograft/tumor models

    PMID:32790649

    Open questions at the time
    • Direct Treg target genes bound by MEF2D not enumerated
    • Structural basis of Foxp3-induced cofactor switch unknown
  13. 2022 High

    Provided atomic-resolution insight into how the MEF2D-HNRNPUL1 fusion gains chromatin binding and dimerization to drive B-ALL, and validated DNA-binding disruption as therapeutic.

    Evidence X-ray crystallography of MEF2D-MRE complex, ChIP-seq, knock-in mouse, mutagenesis, and in vivo leukemia model

    PMID:35544603

    Open questions at the time
    • Whether mechanism generalizes to other MEF2D fusions untested here
    • Full cofactor complex recruited by the HNRNPUL1 moiety not defined
  14. 2024 High

    Established MEF2D as a regulator of innate and adaptive type-2 immunity, repressing Regnase-1 to amplify IL-33 signaling and controlling NFAT1 nuclear translocation.

    Evidence CRISPR screen in ILCs, conditional Mef2d deletion in ILC2s and T cells, allergen lung challenge, and mechanistic readouts

    PMID:38935708

    Open questions at the time
    • Direct vs indirect repression of Regnase-1 not fully separated
    • Mechanism of MEF2D-NFAT1 functional coupling unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the many post-translational modifications, isoform/condensate states, and cell-type-specific cofactors are integrated to produce a single MEF2D activity output in a given tissue remains unresolved.
  • No unified model linking modification state to cofactor choice
  • Quantitative rules governing activator vs repressor switching not defined
  • Mitochondrial vs nuclear partitioning control not mechanistically established

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 7 GO:0003677 DNA binding 5 GO:0140097 catalytic activity, acting on DNA 1
Localization
GO:0005634 nucleus 3 GO:0005829 cytosol 2 GO:0000228 nuclear chromosome 1 GO:0005739 mitochondrion 1
Pathway
R-HSA-74160 Gene expression (Transcription) 6 R-HSA-1643685 Disease 5 R-HSA-168256 Immune System 5 R-HSA-1266738 Developmental Biology 4 R-HSA-5357801 Programmed Cell Death 3 R-HSA-9612973 Autophagy 2
Partners
CRXDAZAP1FOXP3HDAC4HNRNPUL1MEF2ASP1USP14

Evidence

Reading pass · 44 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2009 MEF2D is a substrate of chaperone-mediated autophagy (CMA): MEF2D continuously shuttles to the cytoplasm, interacts with the chaperone Hsc70, and undergoes lysosomal degradation. Inhibition of CMA causes accumulation of inactive MEF2D in the cytoplasm. Alpha-synuclein (wild-type and PD-associated mutant) disrupts MEF2D–Hsc70 binding, blocking CMA-mediated degradation and leading to neuronal death. Co-immunoprecipitation, subcellular fractionation, CMA inhibition assays, neuronal cell line experiments, alpha-synuclein transgenic mouse model Science High 19119233
2011 A portion of MEF2D localizes to neuronal mitochondria via an N-terminal targeting motif and the chaperone mtHsp70, where it binds a MEF2 consensus site in the mitochondrial DNA region containing the ND6 gene (encoding a complex I subunit) and activates ND6 transcription. Blocking mitochondrial MEF2D function decreases complex I activity, increases H2O2, reduces ATP, and sensitizes neurons to stress-induced death. Immunocytochemistry, immunoelectron microscopy, biochemical fractionation, chromatin immunoprecipitation (ChIP) on mtDNA, luciferase reporter, dominant-negative mitochondrial MEF2D construct, mouse PD model (MPTP), postmortem PD brain analysis Journal of Clinical Investigation High 21393861
2009 GSK3β directly phosphorylates MEF2D at three specific residues in its transactivation domain, inhibiting MEF2D transcriptional activity. In cerebellar granule neurons, withdrawal of neuronal activity activates nuclear GSK3β, leading to GSK3β-dependent inhibition of MEF2 function and contributing to neuronal death. Expression of a GSK3β-resistant MEF2D mutant protects neurons from GSK3β activation- or activity deprivation-induced toxicity. In vitro kinase assay, site-directed mutagenesis, cerebellar granule neuron culture, transactivation reporter assays, overexpression of GSK3β-resistant MEF2D mutant Journal of Biological Chemistry High 19801631
2014 Oxidative stress (6-OHDA) causes direct oxidative modifications of MEF2D, which increases its binding affinity for Hsc70 and accelerates its CMA-mediated degradation via upregulation of LAMP2A. An oxidation-resistant MEF2D mutant protects dopaminergic neurons from 6-OHDA-induced death. Oxidized MEF2D is elevated in postmortem PD brains. Biochemical oxidation assays, Co-IP (MEF2D–Hsc70 binding), LAMP2A quantification, MEF2D oxidation-resistant mutant expression, mouse substantia nigra analysis, postmortem PD brain samples Antioxidants & Redox Signaling High 24219011
2014 ATM kinase phosphorylates MEF2D at four ATM consensus sites following DNA damage, activating MEF2D and promoting neuronal survival. ATM associates with MEF2D after DNA damage; a phosphomimetic MEF2D mutant protects cerebellar granule cells from etoposide-induced death, whereas a non-phosphorylatable mutant does not. Mef2d knockout mice show increased cerebellar susceptibility to DNA damage. In vitro kinase assay, Co-immunoprecipitation (ATM–MEF2D), shRNA knockdown, phosphomimetic/non-phosphorylatable mutant rescue, Mef2d knockout mouse cerebellar damage model Journal of Neuroscience High 24672010
2008 MEF2D is required for stress-dependent pathological cardiac remodeling in vivo. MEF2D-null mice are resistant to cardiac hypertrophy, fetal gene activation, and fibrosis in response to pressure overload and beta-adrenergic stimulation. Conversely, transgenic overexpression of MEF2D is sufficient to drive the fetal gene program and pathological cardiac remodeling. Conditional MEF2D knockout mouse, pressure overload model, chronic adrenergic stimulation, MEF2D transgenic overexpression mouse Journal of Clinical Investigation High 18079970
1995 MEF2D is the predominant HeLa cell protein binding the MEF2 site in the c-jun promoter and is required for serum-inducible c-jun expression. Transfection of MEF2D into low-MEF2-activity NIH 3T3 cells reconstitutes serum induction. The MEF2D DNA-binding domain fused to a heterologous activation domain is sufficient for serum induction, suggesting a shared mechanism with SRF-mediated c-fos serum response. DNA-binding assays (EMSA), transfection reconstitution in NIH 3T3 cells, deletion analysis/domain swap Molecular and Cellular Biology High 7760790
2006 At the onset of skeletal muscle specification, MEF2D appears at late muscle gene loci concomitant with the SWI/SNF ATPase Brg1 and chromatin opening. Ectopic co-expression of myogenin and MEF2D (without MyoD) is sufficient to induce muscle differentiation in a manner entirely dependent on Brg1, showing that MEF2D cooperates with myogenin to recruit Brg1 for chromatin remodeling at muscle-specific genes. ChIP in cultured cells and embryonic tissue, ectopic co-expression, Brg1 dominant-negative and knockdown, chromatin accessibility assays EMBO Journal High 16424906
2015 In the retina, MEF2D binds retina-specific enhancers by cooperating with the tissue-specific factor CRX, which recruits MEF2D away from canonical MEF2-binding sites and redirects it to retina-specific enhancers lacking the consensus MEF2 sequence. MEF2D and CRX then co-activate photoreceptor-specific genes critical for retinal function. ChIP-seq, genome-wide MEF2D binding analysis, MEF2D and CRX co-immunoprecipitation, retinal gene expression analysis Neuron High 25801704
2001 14-3-3tau physically interacts with MEF2D (identified by yeast two-hybrid and confirmed by co-precipitation in vivo) and specifically enhances MEF2 transactivational activity by competitively inhibiting HDAC4 from binding to MEF2D, thereby promoting muscle cell differentiation. Yeast two-hybrid, co-immunoprecipitation, transient transfection reporter assay, HDAC4 competition experiment Nucleic Acids Research Medium 11433030
2014 Rbfox2 RNA-binding protein regulates alternative splicing of Mef2d. Restoration of Rbfox2-dependent Mef2d splicing isoforms rescues myoblast fusion in Rbfox2-depleted cultures, demonstrating that Mef2d isoform switching downstream of Rbfox2 is functionally required for myoblast fusion during myogenesis. RNA-seq, Rbfox2 iCLIP, shRNA depletion, splicing isoform rescue experiments in myoblast fusion assays Molecular Cell High 25087874
2013 MEF2D is required for normal myogenesis; its loss in rhabdomyosarcoma cells prevents muscle differentiation. Re-expression of MEF2D in RMS cells activates muscle-specific gene expression (including myosin heavy chain), upregulates p21, inhibits proliferation and motility, and abolishes tumorigenicity in xenograft models. Stable transfection, ChIP (showing absence of MEF2D at muscle gene promoters in RMS), luciferase reporter, proliferation assay, scratch assay, soft agar assay, xenograft tumor model Molecular Cancer Medium 24279793
2019 MEF2D binds the CD274 (PD-L1) gene promoter and activates its transcription in hepatocellular carcinoma cells. Upon IFN-γ stimulation, p300 acetyltransferase acetylates MEF2D and promotes its binding (with acetylated histones) to the CD274 promoter. SIRT7 forms a complex with MEF2D under basal conditions and deacetylates it to attenuate PD-L1 expression; IFN-γ disrupts MEF2D–SIRT7 interaction by inducing p300 binding to MEF2D. ChIP, co-immunoprecipitation, pull-down assays, dual luciferase reporter, MEF2D/SIRT7 knockout cells, allograft tumor models in immune-competent and immune-deficient mice Gastroenterology High 31678303
2009 MEF2D regulates expression of the anti-apoptotic bcl-w gene in dorsal root ganglia sensory neurons downstream of a target-derived neurotrophin–Trk–ERK5/MEF2 pathway, constituting a retrograde survival signaling program. ERK5 activation by distal-axon neurotrophin stimulation induces MEF2D-dependent mef2d and bcl-w expression to promote sensory neuron survival. Neurotrophin compartmentalized axon stimulation, MEF2D expression analysis, ERK5 pathway inhibition, bcl-w reporter and expression assays, sensory neuron survival assays Journal of Neuroscience Medium 19458239
2007 MEF2D is activated by the calcineurin/NFATc1 pathway in muscle cells during calcium-ionophore treatment. MEF2D, NFATc1, and MyoD co-activate the beta-MyHC promoter in a calcineurin-dependent manner; MEF2D binds to the MyoD complex at the promoter and is recruited with p300. This was shown by EMSA, ChIP, and nuclear complex co-immunoprecipitation. EMSA, ChIP, nuclear complex co-immunoprecipitation (NCcoIP), transient transfection reporter assay, calcineurin inhibitor experiments Journal of Cellular Physiology Medium 17111365
2013 CDK5 phosphorylation of MEF2D at Ser444 contributes to MEF2D inactivation and neuronal apoptosis following intracerebral hemorrhage. Knockdown of CDK5 suppresses neuronal apoptosis with concurrent reduction in MEF2D phosphorylation at Ser444. CDK5 kinase activity assay, phospho-specific immunostaining, CDK5 siRNA knockdown, rat intracerebral hemorrhage model, primary cortical neuron culture Journal of Molecular Neuroscience Medium 25417143
2013 MEF2D constitutively binds the Nur77 (NR4A1) promoter in neurons under basal conditions; this binding is lost following MPP+ treatment. MEF2D loss leads to decreased Nur77 expression, sensitizing dopaminergic neurons to MPTP-induced death. Ectopic Nur77 expression in nigrostriatal neurons rescues dopaminergic loss in Nur77-deficient MPTP-treated mice, placing Nur77 downstream of MEF2D in a neuronal survival pathway. ChIP (MEF2D binding to Nur77 promoter), in vivo MPTP mouse model, Nur77 knockout mice, lentiviral Nur77 rescue, striatal dopamine/DOPAC measurement Journal of Biological Chemistry High 23536182
2006 In hippocampal neurons, cAMP inhibits Ca2+-activated MEF2D-mediated gene expression by antagonizing HDAC5 nuclear export (blocking MEF2D derepression) and inhibiting nuclear import of the MEF2 co-activator NFAT3/c4. Unlike CREB, MEF2D is not directly activated by cAMP. Neuronal transfection reporter assays, nuclear/cytoplasmic fractionation, pharmacological cAMP elevation, Ca2+ manipulation in hippocampal neurons Journal of Biological Chemistry Medium 16870618
2016 MEF2D directly regulates transcription of ZEB1 (an EMT driver gene) and facilitates histone acetylation at the ZEB1 promoter in colorectal cancer cells. MEF2D acts as a central integrator of multiple tumor microenvironment signals to activate ZEB1, promoting cancer cell invasion and EMT. ChIP (MEF2D binding to ZEB1 promoter), luciferase reporter, MEF2D knockdown/overexpression, invasion assay, in vivo metastasis model Cancer Research Medium 27364559
2015 MEF2D loss in neonatal cardiomyocytes triggers cell cycle re-entry and programmed cell death. Genome-wide transcriptome analysis showed that MEF2D depletion upregulates positive cell cycle regulators. PTEN, the primary negative regulator of PI3K/Akt, is a direct MEF2D target gene; MEF2D-deficient cardiomyocytes show reduced PTEN and activated PI3K/Akt signaling. siRNA knockdown of MEF2D in neonatal cardiomyocytes, RNA-seq/transcriptome profiling, ChIP (PTEN as direct target), cell cycle analysis, apoptosis assays Journal of Biological Chemistry Medium 26294766
2021 In MLL-rearranged AML, MEF2D binds to and suppresses chromatin accessibility of CEBPE cis-regulatory regions, thereby blocking a CEBPE-centered myeloid differentiation program. Knockout of MEF2D activates CEBPE expression, induces myeloid differentiation, and impairs leukemia growth. CEBPE depletion partially rescues cell growth defects caused by MEF2D loss, placing MEF2D upstream of CEBPE in a leukemia self-renewal circuit. MEF2D knockout (CRISPR), RNA-seq, ATAC-seq/chromatin profiling (ChIP), CEBPE depletion rescue, in vivo leukemia progression model Blood Advances High 34597364
2022 The MEF2D-HNRNPUL1 (MH) fusion protein acquires increased chromatin-binding ability at MEF2D-responsive element (MRE) motifs. X-ray crystallography of the MEF2D-MRE complex revealed atomic-resolution structure. Disrupting MH–DNA interaction alleviated aberrant target gene expression and B-cell differentiation arrest. The HNRNPUL1 C-terminal moiety contributes to trans-regulatory activity, cofactor recruitment, and homodimerization of the fusion protein. Knock-in mouse model, RNA-seq, ChIP-seq, X-ray crystallography, MH–DNA interaction mutagenesis, HDAC inhibitor treatment, xenograft/in vivo leukemia model Blood High 35544603
2013 O-GlcNAc glycosylation of MEF2D (specifically the Mef2D1a splice variant, in both its DNA-binding and transactivation domains) negatively regulates MEF2D recruitment to the myogenin promoter. Decreased O-GlcNAc glycosylation upon myogenic stimulus is required for MEF2D binding to the myogenin promoter and subsequent myogenin expression. O-GlcNAc glycosylation assays, deletion mutant analysis, O-GlcNAc transferase/hydrolase inhibitors, ChIP (MEF2D at myogenin promoter), C2C12 differentiation model Biochemical and Biophysical Research Communications Medium 23523791
2002 MEF2D forms a protein complex with Sp1 in U937 promyeloid cells. Co-expression of MEF2D and Sp1 synergistically activates the CD14 promoter during monocytic differentiation, providing a mechanism for MEF2D to regulate gene expression at promoters lacking canonical MEF2-binding sites. Co-immunoprecipitation (MEF2D–Sp1 complex), transient transfection reporter assay, CD14 promoter activation analysis Molecular Immunology Medium 12213324
2010 MEF2D forms high-level MEF2A–MEF2D heterodimers in macrophage-differentiated HL60 cells. MEF2A/D dimers strongly interact with HDAC1 (and to a lesser extent HDAC7) in macrophages, and only in differentiated macrophages does endogenous p300 associate with MEF2A—suggesting that MEF2A/D can act as either repressors (via HDAC1/7) or activators (via p300) of target genes including c-Jun. Co-immunoprecipitation, ChIP (MEF2A on c-Jun promoter), HDAC inhibitor experiments, differentiation assays Biochemical Journal Medium 20590529
1999 MEF2D is required for monocyte/macrophage differentiation: expression of a dominant-negative MEF2D (lacking transactivation domain) in HL60 cells significantly decreases CD14 surface expression and NBT reduction ability upon VitD3-induced differentiation. Dominant-negative MEF2D stable expression, flow cytometry (CD14), NBT reduction assay, HL60 differentiation model Molecular Immunology Medium 10684960
2012 In Xenopus, Mef2d acts upstream of MyoD to transactivate Myod expression in lateral presomitic cells required for lateral myogenesis, and also cooperates with Paraxis (Tcf15) to directly activate Meox2 expression upstream of Pax3 in dermomyotome formation progenitors. Gain- and loss-of-function experiments establish Mef2d as an upstream regulator coupling lateral myogenesis to dermomyotome formation. Gain-of-function (mRNA injection) and loss-of-function (morpholino) in Xenopus, cell tracing, in situ hybridization, promoter reporter assays for Myod and Meox2 PLOS ONE Medium 23300648
2021 MEF2D activates transcription of NR4A1 (Nur77) and the reticulophagy receptor FAM134B2 gene under amino acid deficiency, as part of a MEF2D–NR4A1–FAM134B2-mediated reticulophagy pathway that contributes to amino acid homeostasis. Luciferase reporter assays, MEF2D ChIP, amino acid deprivation experiments, reticulophagy flux assays Autophagy Low 34517786
2017 In hepatocellular carcinoma, MEF2D in complex with HDAC4 directly binds the SPRY4 promoter and suppresses SPRY4 transcription, thereby relieving SPRY4-mediated inhibition of the MAPK/ERK pathway and contributing to sorafenib resistance. ChIP (MEF2D and HDAC4 binding to SPRY4 promoter), Co-immunoprecipitation (MEF2D–HDAC4 complex), HDAC4 inhibitor experiments, sorafenib resistance assays, in vivo tumor model Cancer Letters Medium 34339801
2020 In CD4+Foxp3+ Treg cells, MEF2D interacts with Foxp3 and is released from canonical HDAC partners, gaining new functions. MEF2D is required for expression of IL-10, CTLA4, and Icos and for effector Treg phenotype acquisition, acting downstream of Blimp1. Conditional MEF2D deletion in Tregs impairs long-term allograft survival and enhances anti-tumor immunity. Conditional MEF2D knockout in Tregs, Co-immunoprecipitation (MEF2D–Foxp3), gene expression analysis, allograft survival model, syngeneic tumor model Journal of Clinical Investigation High 32790649
2024 In ILC2s and CD4 T cells, Mef2d promotes type-2 immunity by repressing Regnase-1 endonuclease expression to enhance IL-33 receptor (ST2) levels and IL-33 signaling, and acts downstream of calcium-mediated signaling to translocate NFAT1 to the nucleus to promote type-2 cytokine production. CRISPR screen in ILCs identified Mef2d as a regulator of GATA3-dependent type-2 lymphocyte differentiation. CRISPR screens in ILCs, Mef2d conditional deletion from ILC2s and T cells, allergen lung challenge model, Regnase-1/ST2 expression analysis, NFAT1 nuclear translocation assay Science High 38935708
2023 In CD4 T cells, Mef2d negatively regulates Sh2d1a (encoding SAP) expression via DNA binding-dependent transcriptional repression, inhibiting SAP-dependent B:T synapse formation and preventing differentiation of antigen-specific CD4 T cells into GC-TFH cells. Mef2d also directly represses the Il21 gene, reducing IL-21 production. Mef2d CD4 T cell-specific KO, SAP expression analysis, GC-TFH differentiation assays after protein immunization, luciferase reporter for Il21 and Sh2d1a, ChIP for MEF2D binding Science Immunology High 36961907
2023 The alternatively spliced β-domain of Mef2D promotes formation of mobile nuclear condensates (liquid-liquid phase separation) and solid-like cytosolic aggregates in C2C12 cells. Aggregate formation correlates with higher transcriptional activity and enhanced MyoD/desmin expression. NMR and molecular dynamics simulations show the β-domain samples both ordered and disordered conformations, fine-tuning Mef2D higher-order assembly as a platform for myogenic regulatory factors during differentiation. NMR spectroscopy, molecular dynamics simulations, live-cell imaging of nuclear condensates, immunofluorescence for aggregates, transcriptional reporter assays, C2C12 myogenesis model Nature Communications High 36898987
2023 MEF2D transactivates Itgb1 (β1-integrin) and Itgb4 (β4-integrin) to facilitate disseminated cancer cell adhesion and colonization during intrahepatic metastasis. An integrin-FAK circuit promotes USP14-mediated deubiquitination of MEF2D at a phospho-Ser432-dependent switch, stabilizing MEF2D by preventing MDM2-mediated ubiquitin-proteasomal degradation. Motif enrichment analysis, ChIP (MEF2D at Itgb1/Itgb4 promoters), Co-IP (MEF2D–USP14, MEF2D–MDM2), ubiquitination assay, phospho-specific mutants, in vivo intrahepatic metastasis model Advanced Science Medium 37828611
2016 MEF2D rearrangements (e.g., MEF2D-BCL9, MEF2D-DAZAP1, MEF2D-HNRNPUL1, MEF2D-SS18) result in enhanced MEF2D transcriptional activity, lymphoid transformation, and activation of HDAC9 expression in B-ALL. MEF2D-rearranged ALL is sensitive to HDAC inhibitor treatment. RNA sequencing of 560 ALL cases, functional transformation assays, HDAC9 reporter/expression analysis, HDAC inhibitor sensitivity testing Nature Communications Medium 27824051
2005 The MEF2D/DAZAP1 fusion protein (from variant t(1;19) ALL translocation) binds DNA with the same specificity as wild-type MEF2D but is a substantially more potent transcriptional activator. The reciprocal DAZAP1/MEF2D fusion retains sequence-specific RNA-binding activity. EMSA (DNA binding), transient transfection reporter assays (transcriptional activation), RNA binding assays Leukemia Medium 15744350
2007 Both MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins transform NIH 3T3 cells (soft agar colony formation ~20-fold above vector), and co-expression of both is synergistic (~3-fold additional increase). Wild-type DAZAP1, MEF2D, and DAZAP1/MEF2D support proliferation under low serum and suppress apoptosis, while MEF2D/DAZAP1 does not. Retroviral gene transfer, soft agar colony formation assay, low-serum proliferation assay, apoptosis assays in NIH 3T3 cells Leukemia Medium 17898785
2008 Muscle contraction per se rapidly increases MEF2D binding activity at the SLC2A4 (GLUT4) gene promoter in soleus muscle, contributing to GLUT4 mRNA and protein upregulation. This was confirmed by EMSA/supershift and ChIP showing ~4-fold increase in MEF2D occupancy at the promoter after electrical stimulation. EMSA, supershift assay, ChIP on native nucleosomes, electrically-induced contraction in vitro, qPCR and protein quantification American Journal of Physiology—Endocrinology and Metabolism Medium 18957617
2021 In Treg cells, loss of Mef2c induces expression of HDAC9, which then converts Mef2d (the more abundant family member) into a transcriptional repressor at the Il10 and Icos loci, impairing Treg suppressive functions. This defines a Mef2c–HDAC9–Mef2d regulatory circuit controlling effector Treg gene expression. Mef2c conditional KO in Tregs, HDAC9 expression analysis, Mef2d ChIP at Il10/Icos loci, syngeneic tumor model Frontiers in Immunology Medium 34290714
2017 KDM1A (LSD1) demethylase interacts with MEF2D and acts as a demethylase to reduce MEF2D methylation; demethylated MEF2D binds the PD-L1 (CD274) promoter and activates its expression in hepatocellular carcinoma cells. Co-immunoprecipitation (KDM1A–MEF2D), methylation analysis, luciferase reporter assay, CRISPR-KO cells, ChIP Journal of Immunology Research Medium 34307695
2017 MEF2D haploinsufficiency reduces NRF2 transcription in photoreceptors. Reactive oxygen species cause aberrant redox modification of MEF2D in the retina, inhibiting its transcription of the downstream target NRF2, a master regulator of antioxidant gene expression. This contributes to accelerated photoreceptor death under light-induced oxidative stress. Mef2d+/- mouse retina, light-induced retinal degeneration model, MEF2D redox modification assay, NRF2 reporter and expression analysis, proelectrophilic drug rescue PNAS Medium 28461502
2019 The lncRNA EPIC1 binds MEF2D protein directly (confirmed by RNA pull-down and RIP) and promotes MEF2D ubiquitylation, leading to MEF2D protein degradation and inhibition of osteosarcoma cell viability and invasion. RNA pull-down, RNA immunoprecipitation (RIP), ubiquitination assay, co-transfection rescue, xenograft tumor model International Journal of Biological Macromolecules Low 30703420
2019 Pokemon (ZBTB7A) transcription factor binds two recognition sites within the MEF2D promoter upstream region and enhances MEF2D transcription in hepatocellular carcinoma cells, thereby promoting HCC invasiveness. ChIP (Pokemon binding to MEF2D promoter), luciferase reporter assay, Pokemon knockdown, MEF2D rescue experiment, transwell invasion assay, in vivo metastasis model Hepatology International Medium 26797719
2019 MEF2D directly binds the SORBS2 gene promoter and reduces SORBS2 expression in hepatocellular carcinoma, with MEF2D acting as an upstream repressor of SORBS2 which in turn inhibits HCC metastasis via the c-Abl/ERK signaling pathway. ChIP (MEF2D at SORBS2 promoter), luciferase reporter, MEF2D knockdown, in vivo metastasis model American Journal of Cancer Research Low 31911856

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2009 Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science (New York, N.Y.) 258 19119233
2016 Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nature communications 235 27824051
2008 The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. The Journal of clinical investigation 209 18079970
1995 Regulatory role of MEF2D in serum induction of the c-jun promoter. Molecular and cellular biology 165 7760790
2011 Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients. The Journal of clinical investigation 140 21393861
2006 Skeletal muscle specification by myogenin and Mef2D via the SWI/SNF ATPase Brg1. The EMBO journal 121 16424906
2014 Rbfox2-coordinated alternative splicing of Mef2d and Rock2 controls myoblast fusion during myogenesis. Molecular cell 103 25087874
2016 MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 97 27507882
2019 Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. Gastroenterology 96 31678303
2014 Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2-M transition genes. Cancer research 86 24390737
2014 Oleanolic acid suppresses the proliferation of lung carcinoma cells by miR-122/Cyclin G1/MEF2D axis. Molecular and cellular biochemistry 85 25472877
2018 Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion. Haematologica 70 30171027
2015 miR-103 promotes 3T3-L1 cell adipogenesis through AKT/mTOR signal pathway with its target being MEF2D. Biological chemistry 68 25400071
2015 MEF2D drives photoreceptor development through a genome-wide competition for tissue-specific enhancers. Neuron 68 25801704
2016 MEF2D Transduces Microenvironment Stimuli to ZEB1 to Promote Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer. Cancer research 65 27364559
2009 A retrograde neuronal survival response: target-derived neurotrophins regulate MEF2D and bcl-w. The Journal of neuroscience : the official journal of the Society for Neuroscience 62 19458239
2017 Methylene blue attenuates neuroinflammation after subarachnoid hemorrhage in rats through the Akt/GSK-3β/MEF2D signaling pathway. Brain, behavior, and immunity 61 28457811
2007 Activation of the beta myosin heavy chain promoter by MEF-2D, MyoD, p300, and the calcineurin/NFATc1 pathway. Journal of cellular physiology 61 17111365
2014 Oxidation of survival factor MEF2D in neuronal death and Parkinson's disease. Antioxidants & redox signaling 57 24219011
2017 MiR-421 inhibits the malignant phenotype in glioma by directly targeting MEF2D. American journal of cancer research 54 28469958
2009 Phosphorylation of neuronal survival factor MEF2D by glycogen synthase kinase 3beta in neuronal apoptosis. The Journal of biological chemistry 53 19801631
2006 Differential effects of Ca2+ and cAMP on transcription mediated by MEF2D and cAMP-response element-binding protein in hippocampal neurons. The Journal of biological chemistry 53 16870618
2016 Multifunction of Chrysin in Parkinson's Model: Anti-Neuronal Apoptosis, Neuroprotection via Activation of MEF2D, and Inhibition of Monoamine Oxidase-B. Journal of agricultural and food chemistry 49 27245668
2010 Dual roles for MEF2A and MEF2D during human macrophage terminal differentiation and c-Jun expression. The Biochemical journal 49 20590529
2005 Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia. Leukemia 47 15744350
2019 ZEB1 activated-VPS9D1-AS1 promotes the tumorigenesis and progression of prostate cancer by sponging miR-4739 to upregulate MEF2D. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 41 31918265
1995 Expression of a MADS box gene, MEF2D, in neurons of the mouse central nervous system: implication of its binary function in myogenic and neurogenic cell lineages. Neuroscience letters 40 8614558
2012 Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects. The Journal of biological chemistry 39 22891246
2019 Long non-coding RNA Irm enhances myogenic differentiation by interacting with MEF2D. Cell death & disease 38 30792383
2023 Dexmedetomidine abates myocardial ischemia reperfusion injury through inhibition of pyroptosis via regulation of miR-665/MEF2D/Nrf2 axis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 36 37549462
2021 KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D. Journal of immunology research 36 34307695
2003 A myocyte enhancer factor 2D (MEF2D) kinase activated during neuronal apoptosis is a novel target inhibited by lithium. Journal of neurochemistry 35 12787068
2018 Neuroprotection Against MPP+-Induced Cytotoxicity Through the Activation of PI3-K/Akt/GSK3β/MEF2D Signaling Pathway by Rhynchophylline, the Major Tetracyclic Oxindole Alkaloid Isolated From Uncaria rhynchophylla. Frontiers in pharmacology 33 30072894
2013 Perturbation of transcription factor Nur77 expression mediated by myocyte enhancer factor 2D (MEF2D) regulates dopaminergic neuron loss in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The Journal of biological chemistry 33 23536182
2013 Loss of MEF2D expression inhibits differentiation and contributes to oncogenesis in rhabdomyosarcoma cells. Molecular cancer 32 24279793
2010 Dysregulation of autophagy and Parkinson's disease: the MEF2D link. Apoptosis : an international journal on programmed cell death 32 20165919
2007 Cooperative transformation by MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins generated by the variant t(1;19) in acute lymphoblastic leukemia. Leukemia 30 17898785
2001 The MEF2A and MEF2D isoforms are differentially regulated in muscle and adipose tissue during states of insulin deficiency. Endocrinology 30 11316766
2016 MEF2D/Wnt/β-catenin pathway regulates the proliferation of gastric cancer cells and is regulated by microRNA-19. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 29 26762410
2015 Indirubin-3-Oxime Effectively Prevents 6OHDA-Induced Neurotoxicity in PC12 Cells via Activating MEF2D Through the Inhibition of GSK3β. Journal of molecular neuroscience : MN 29 26346600
2017 MEF2D haploinsufficiency downregulates the NRF2 pathway and renders photoreceptors susceptible to light-induced oxidative stress. Proceedings of the National Academy of Sciences of the United States of America 28 28461502
2015 Mef2d is essential for the maturation and integrity of retinal photoreceptor and bipolar cells. Genes to cells : devoted to molecular & cellular mechanisms 28 25757744
2015 miR-218 suppressed the growth of lung carcinoma by reducing MEF2D expression. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 28 26409449
2014 Destabilization of survival factor MEF2D mRNA by neurotoxin in models of Parkinson's disease. Journal of neurochemistry 28 24848448
2020 MiR-421 Aggravates Neurotoxicity and Promotes Cell Death in Parkinson's Disease Models by Directly Targeting MEF2D. Neurochemical research 27 33179210
2017 MiR-665 regulates VSMCs proliferation via targeting FGF9 and MEF2D and modulating activities of Wnt/β-catenin signaling. American journal of translational research 27 29118903
2010 6-Hydroxydopamine-induced PC12 cell death is mediated by MEF2D down-regulation. Neurochemical research 26 21057871
2020 Silencing of MEF2D by siRNA Loaded Selenium Nanoparticles for Ovarian Cancer Therapy. International journal of nanomedicine 25 33304100
2019 Long non-coding RNA EPIC1 inhibits viability and invasion of osteosarcoma cells by promoting MEF2D ubiquitylation. International journal of biological macromolecules 25 30703420
2019 Long noncoding RNA DLEU1 aggravates glioma progression via the miR-421/MEF2D axis. OncoTargets and therapy 25 31360066
2015 MEF2D overexpression contributes to the progression of osteosarcoma. Gene 25 25814384
2024 Mef2d potentiates type-2 immune responses and allergic lung inflammation. Science (New York, N.Y.) 24 38935708
2020 MEF2D sustains activation of effector Foxp3+ Tregs during transplant survival and anticancer immunity. The Journal of clinical investigation 24 32790649
2019 SORBS2, mediated by MEF2D, suppresses the metastasis of human hepatocellular carcinoma by inhibitiing the c-Abl-ERK signaling pathway. American journal of cancer research 24 31911856
2016 β-asarone increases MEF2D and TH levels and reduces α-synuclein level in 6-OHDA-induced rats via regulating the HSP70/MAPK/MEF2D/Beclin-1 pathway: Chaperone-mediated autophagy activation, macroautophagy inhibition and HSP70 up-expression. Behavioural brain research 24 27444243
2014 CDK5 contributes to neuronal apoptosis via promoting MEF2D phosphorylation in rat model of intracerebral hemorrhage. Journal of molecular neuroscience : MN 24 25417143
2008 The glucose-lowering agent sodium tungstate increases the levels and translocation of GLUT4 in L6 myotubes through a mechanism associated with ERK1/2 and MEF2D. Diabetologia 24 18483800
2008 Contractile activity per se induces transcriptional activation of SLC2A4 gene in soleus muscle: involvement of MEF2D, HIF-1a, and TRalpha transcriptional factors. American journal of physiology. Endocrinology and metabolism 24 18957617
2021 MEF2D-NR4A1-FAM134B2-mediated reticulophagy contributes to amino acid homeostasis. Autophagy 23 34517786
2019 Salidroside protects dopaminergic neurons by regulating the mitochondrial MEF2D-ND6 pathway in the MPTP/MPP+ -induced model of Parkinson's disease. Journal of neurochemistry 22 31520529
2015 MEF2D deficiency in neonatal cardiomyocytes triggers cell cycle re-entry and programmed cell death in vitro. The Journal of biological chemistry 22 26294766
2014 ATM-dependent phosphorylation of MEF2D promotes neuronal survival after DNA damage. The Journal of neuroscience : the official journal of the Society for Neuroscience 22 24672010
2013 Requirement of decreased O-GlcNAc glycosylation of Mef2D for its recruitment to the myogenin promoter. Biochemical and biophysical research communications 22 23523791
2022 Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusion. Blood 21 35544603
2021 Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia. Blood advances 21 34597364
2019 Protocatechuic acid attenuates β‑secretase activity and okadaic acid‑induced autophagy via the Akt/GSK‑3β/MEF2D pathway in PC12 cells. Molecular medicine reports 21 31894327
2017 Substantial protection against MPTP-associated Parkinson's neurotoxicity in vitro and in vivo by anti-cancer agent SU4312 via activation of MEF2D and inhibition of MAO-B. Neuropharmacology 21 28807675
2017 Overexpression and biological function of MEF2D in human pancreatic cancer. American journal of translational research 21 29218083
2016 Pokemon promotes the invasiveness of hepatocellular carcinoma by enhancing MEF2D transcription. Hepatology international 21 26797719
2020 Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia. Blood cancer discovery 20 34661142
2007 MEF2D expression increases during neuronal differentiation of neural progenitor cells and correlates with neurite length. Neuroscience letters 20 17945419
2021 Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance. Cancer letters 19 34339801
2016 MEF2D and MEF2C pathways disruption in sporadic and familial ALS patients. Molecular and cellular neurosciences 19 26921792
2012 Mef2d acts upstream of muscle identity genes and couples lateral myogenesis to dermomyotome formation in Xenopus laevis. PloS one 19 23300648
2023 The transcription factor Mef2d regulates B:T synapse-dependent GC-TFH differentiation and IL-21-mediated humoral immunity. Science immunology 18 36961907
2020 miR-217-regulated MEF2D-HDAC5/ND6 signaling pathway participates in the oxidative stress and inflammatory response after cerebral ischemia. Brain research 18 32311345
2009 The complexity in regulation of MEF2D by chaperone-mediated autophagy. Autophagy 18 19738442
2021 Isoflurane post-conditioning contributes to anti-apoptotic effect after cerebral ischaemia in rats through the ERK5/MEF2D signaling pathway. Journal of cellular and molecular medicine 17 33621420
2017 Effect of miR-1244 on cisplatin-treated non-small cell lung cancer via MEF2D expression. Oncology reports 17 28498474
2019 Overexpression of MEF2D contributes to oncogenic malignancy and chemotherapeutic resistance in ovarian carcinoma. American journal of cancer research 16 31218100
2018 miR-30a suppresses osteosarcoma proliferation and metastasis by downregulating MEF2D expression. OncoTargets and therapy 16 29713188
2017 Downregulation of miR-30a is associated with proliferation and invasion via targeting MEF2D in cervical cancer. Oncology letters 16 29344185
2016 MEF2D Mediates the Neuroprotective Effect of Methylene Blue Against Glutamate-Induced Oxidative Damage in HT22 Hippocampal Cells. Molecular neurobiology 16 26941101
2016 PPARγ suppresses the proliferation of cardiac myxoma cells through downregulation of MEF2D in a miR-122-dependent manner. Biochemical and biophysical research communications 16 27109478
2014 Comparative analysis reveals distinct and overlapping functions of Mef2c and Mef2d during cardiogenesis in Xenopus laevis. PloS one 16 24489892
2001 14-3-3tau associates with and activates the MEF2D transcription factor during muscle cell differentiation. Nucleic acids research 16 11433030
1999 Requirement of MEF2D in the induced differentiation of HL60 promyeloid cells. Molecular immunology 16 10684960
2023 A Ubiquitin-Dependent Switch on MEF2D Senses Pro-Metastatic Niche Signals to Facilitate Intrahepatic Metastasis of Liver Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 14 37828611
2019 MiR-335 promotes cell proliferation by inhibiting MEF2D and sensitizes cells to 5-Fu treatment in gallbladder carcinoma. European review for medical and pharmacological sciences 14 31799650
2018 The pathogenic role of MEF2D-SS18 fusion gene in B-cell acute lymphoblastic leukemia. Biochemical and biophysical research communications 14 29408457
2018 Absent expression of miR-30a promotes the growth of lung cancer cells by targeting MEF2D. Oncology letters 14 29963192
2018 A rare regulatory variant in the MEF2D gene affects gene regulation and splicing and is associated with a SLE sub-phenotype in Swedish cohorts. European journal of human genetics : EJHG 14 30459414
2022 LncRNA CASC15 regulates breast cancer cell stemness via the miR-654-5p/MEF2D axis. Journal of biochemical and molecular toxicology 13 35235236
2021 A Biological Circuit Involving Mef2c, Mef2d, and Hdac9 Controls the Immunosuppressive Functions of CD4+Foxp3+ T-Regulatory Cells. Frontiers in immunology 13 34290714
2020 CircCPA4 Promotes the Malignant Phenotypes in Glioma via miR-760/MEF2D Axis. Neurochemical research 13 33068224
2019 Association between PRDM16, MEF2D, TRPM8, LRP1 gene polymorphisms and migraine susceptibility in the She ethnic population in China. Clinical and investigative medicine. Medecine clinique et experimentale 13 30904033
2002 Synergistic interaction of MEF2D and Sp1 in activation of the CD14 promoter. Molecular immunology 12 12213324
2023 Alternatively spliced exon regulates context-dependent MEF2D higher-order assembly during myogenesis. Nature communications 11 36898987
2020 Loss of Mef2D function enhances TLR induced IL-10 production in macrophages. Bioscience reports 11 32725155
2022 MEF2D Participates in Microglia-Mediated Neuroprotection in Cerebral Ischemia-Reperfusion Rats. Shock (Augusta, Ga.) 10 34905532

Missed literature

Know a paper Affinage missed for MEF2D? Flag it for the maintainers and the community.

No submissions yet.